Atopic Dermatitis

Drs Noor and Lamb discuss mechanisms of action of biologics and JAK inhibitors and the importance of patient communication while selecting AD treatments.

Drs Lamb, Noor, and Bhatia discuss their approach to selecting treatment in light of recent AD approvals.

Drs Noor and Lamb highlight the importance of frank discussion of adverse effects of atopic dermatitis treatments with patients.

Drs Bhatia, Lamb and Noor talk about the importance of building trust with patients and highlight topics to discuss with patients and parents.

Dermatology experts discuss strategies to increase awareness of advances in AD in patients with SOC.

Drs. Neal Bhatia and Angela Lamb provide an overview of atopic dermatitis and its prevalence in patients with skin of color (SOC).

A better understanding of this atopic diathesis and the atopic march often seen in pediatric patients is necessary to optimally treat and manage the patient population, ideally in a multidisciplinary setting.

In this episode, Raj Chovatiya, MD, PhD, and assistant professor of dermatology and director of the Center for Ecezma and Itch at the Northwestern University Feinberg School of Medicine, discusses the changing field of atopic dermatitis, the importance of JAK inhibitors, and the treatment options he looks forward to.

At the SPD 2022 47th Annual Meeting in Indianapolis, Indiana, Candrice Heath shares her takeaways "Atopic dermatitis in skin of color."

At the SPD 2022 47th Annual Meeting in Indianapolis, Candrice R. Heath, MD, FAAP, FAAD shares compelling best practices for treating patients of color with this condition.

Sleep disturbance is a significant factor in reduced quality of life for children and adolescents. A study at a poster session for the SPD 2022 47th Annual Meeting was presented on treating this population with dupilumab (Dupixent) to help with sleep quality showed positive results.

At the SPD 2022 47th Annual Meeting in Indianapolis, Indiana, a poster session on atopic dermatitis severity and outcomes in young children from 5 regions around the world.

Cynthia J. Trickett, PA-C, MPAS, discusses the personal and clinical effects of atopic dermatitis in adult and pediatric patients at the Maui Derm NP+PA 2022 Summer Conference in Colorado Springs, Colorado.

An extraordinary display of posters at this year's Society for Pediatric Dermatology annual conference.

From pediatric dermatology quizzes to the latest news in telederm to practical pearls on atopic dermatitis, alopecia, and vitiligo, there’s a lot going on at the SPD 2022 47th Annual Meeting, this year in Indianapolis, Indiana.

Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics and vice-chair of the department of dermatology at UC San Diego School of Medicine, discusses new treatments and therapies for pediatric atopic dermatitis.

Click here to answer this week's poll.

Eric Simpson, MD, MCR, director of clinical research and dermatology professor at the Frances J. Storrs medical school at Oregon Health & Science University in Portland, Oregon, explains dives into what 2022 is bringing to the AD space.

Eric Simpson, MD, MCR, director of clinical research and dermatology professor at the Frances J. Storrs medical school at Oregon Health & Science University in Portland, Oregon, details the environment factors that could impact atopic dermatitis.

Here is what to expect from the “Getting to the Roots of Childhood Atopic Dermatitis” live virtual webinar happening June 23, 2022, at 6:00 PM EST.

At the 2022 SDPA Annual Summer Meeting, Lisa Swanson, MD, shared some fascinating patient presentations in pediatric dermatology.

A recent study showed that patients with atopic dermatitis have a higher prevalence of infertility, highlighting the need for clinicians to be wary of this increased risk and improve the care and management of this patient population.

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, who discusses the importance of multidisciplinary in the dermatology specialty.

Amy Paller, MD, chair of the Department of Dermatology at Northwestern University’s Feinberg School of Medicine, sits down to answer the important questions on this FDA approval.

Sanofi and Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis

About 80% of patients treated with roflumilast foam 0.3% (ARQ-154, Arcutis Biotherapeutics Inc) met the primary endpoint of the trial.

In a video with Dermatology Times®, James Q. Del Rosso, DO, discusses his presentation “What’s News in the Medicine Chest” at the current 2022 Fall Clinical Dermatology Conference for PAs & NPs.

A poster presented at the current 2022 Fall Clinical Dermatology Conference for PAs & NPs showed normalization of skin barrier function in patients with moderate to severe atopic dermatitis taking dupilumab, according to the investigators.

Matthew Zirwas, MD, shares his step-by-step pearls for quelling this pruritic skin condition.

Patients with chronic inflammatory skin diseases do not have an increased risk of venous thromboembolism (VTE) compared to a matched healthy control cohort. This knowledge can be useful to clinicians when contemplating systemic immunomodulatory therapies in their dermatologic patients.